Hikma Pharmaceuticals’ (HIK) Hold Rating Reiterated at Berenberg Bank

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “hold” rating reaffirmed by equities research analysts at Berenberg Bank in a research note issued to investors on Thursday, Digital Look reports. They currently have a GBX 2,000 ($24.70) price target on the stock. Berenberg Bank’s price target would suggest a potential upside of 5.10% from the stock’s current price.

Separately, Barclays reaffirmed an “equal weight” rating and set a GBX 2,000 ($24.70) price target on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of GBX 2,068.75 ($25.55).

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at GBX 1,903 ($23.51) on Thursday. Hikma Pharmaceuticals has a 12-month low of GBX 1,711 ($21.13) and a 12-month high of GBX 2,222 ($27.45). The company has a market capitalization of £4.22 billion, a price-to-earnings ratio of 2,840.30, a price-to-earnings-growth ratio of 2.38 and a beta of 0.45. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27. The firm’s fifty day moving average price is GBX 1,888.99 and its 200 day moving average price is GBX 1,870.84.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.